Bisphosphonates have become an important treatment for the palliation of metastatic bone disease. Their increasing use has lead to the recognition of toxicities that can lead to substantial morbidity for the patient with advanced cancer. This case presentation highlights toxicities associated with bisphosphonate use and provides some guidelines on the use of bisphosphonates and management of these toxicities.
Get full access to this article
View all access options for this article.
References
1.
WooSB, HellsteinJW, KalmarJR. Systematic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med, 2006; 144:753–761.
2.
von MoosR, StrasserF, GillessenS, ZauggK. Metastatic bone pain: Treatment options with an emphasis on bisphosphonates. Support Care Cancer, 2008; 16:1105–1115.
3.
SabinoMA, MantyhPW. Pathophysiology of bone cancer pain. J Support Oncol, 2005; 3:15–24.
4.
BamiasA, KastritisE, BamiaC, MoulopoulosLA, MelakopoulosI, BozasG, KoutsoukouV, GikaD, AnagnostopoulosA, PapadimitriouC, TerposE, DimopoulosMA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol, 2005; 23:8580–8587.
5.
BodyJJ, ColemanR, ClezardinP, RipamontiC, RizzoliR, AaproM. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer, 2007; 43:852–858.
6.
LinJH. Bisphosphonates: A review of their pharmacokinetic properties. Bone, 1996; 18:75–85.
7.
SenelFC, SaracogluTU, DurmusA, BagisB. Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): Report of a case. J Oral Maxillofac Surg, 2007; 65:562–565.
8.
YehHS, BerensonJR. Treatment for myeloma bone disease. Clin Cancer Res, 2006; 12:6279s–66284.
9.
ClarkeBM, BoyetteJ, VuralE, SuenJY, AnaissieEJ, StackBCJr. Bisphosphonates and jaw osteonecrosis: The UAMS experience. Otolaryngol Head Neck Surg, 2007; 136:396–400.
10.
BertoldoF, SantiniD, Lo CascioV. Bisphosphonates and osteomyelitis of the jaw: A pathogenic puzzle. Nat Clin Pract Oncol, 2007; 4:711–721.
11.
EstiloCL, Van PoznakCH, WiliamsT, BohleGC, LwinPT, ZhouQ, RiedelER, CarlsonDL, SchoderH, FarookiA, FornierM, HalpernJL, TunickSJ, HurynJM. Osteonecrosis of the maxilla and mandible in Patients with advanced cancer treated with bisphosphonate therapy. Oncologist, 2008; 13:911–920.
12.
SciubbaJJ, GoldenbergD. Oral complications of radiotherapy. Lancet Oncol, 2006; 7:175–183.
13.
JacksonGH. Renal safety of ibandronate. Oncologist, 2005; 10,Suppl 1:14–18.
14.
DielIJ, BergnerR, GrotzKA. Adverse effects of bisphosphonates: Current issues. J Support Oncol, 2007; 5:475–482.
15.
ChangJT, GreenL, BeitzJ. Renal failure with the use of zoledronic acid. N Engl J Med, 2003; 349:1676–1679.
16.
TanvetyanonT, StiffPJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol, 2006; 17:897–907.
17.
BerensonJR, VescioRA, RosenLS, VonTeichertJM, WooM, SwiftR, SavageA, GivantE, HupkesM, HarveyH, LiptonA. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res, 2001; 7:478–485.
BergnerR, DielIJ, HenrichD, HoffmannM, UppenkampM. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie, 2006; 29:534–540.
22.
SaadF, GleasonDM, MurrayR, TchekmedyianS, VennerP, LacombeL, ChinJL, VinholesJJ, GoasJA, ChenB. Zoledronic Acid Prostate Cancer Study Group: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002; 94:1458–1468.
23.
DicuonzoG, VincenziB, SantiniD, AvvisatiG, RocciL, BattistoniF, GavasciM, BorzomatiD, CoppolaR, ToniniG. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res, 2003; 23:649–654.
24.
FraunfelderFW, FraunfelderFT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology, 2004; 111:1275–1279.
25.
MooreMM, BeithJM. Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust, 2008; 188:370–371.
26.
ZOMETA®IV injection, zoledronic acid IV injection [product information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2008.
27.
AREDIA®IV injection, pamidronate disodium IV injection [product information]. East Hanover, NJ: Novartis, 2008.
28.
DevittB, McLachlanSA. Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther Clin Risk Manag, 2008; 4:453–458.
